Top Injectable Manufacturer in Georgia – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 1 day ago
- 11 min read
Last Updated: August 28, 2026
TL;DR: Georgia is famous for a seven-working-day medicines registration, and for an Indian manufacturer that headline is the wrong one to read. The Law on Medicines and Pharmaceutical Activities creates two separate routes: a recognition regime, which unilaterally accepts approvals from a fixed list of foreign regulators and skips the scientific assessment entirely, and a national regime, which is a full technical review. The recognised list is set by Government Resolution No. 188 of 22 October 2009 and its three amendments, and India is not on it – neither is WHO Prequalification. So the fast lane is shut and the national lane is the one that matters. The good news is that the national lane is unusually workable: WHO-GMP is an expressly recognised standard in Georgia, the statutory fee for a generic is GEL 500, the decision clock is three months, the Agency may raise deficiencies only twice, and if it says nothing in time the product is deemed registered. The real costs are Georgian-language filing, three paper copies and physical samples with reference standards – not the fee.
Key Takeaways
Georgia's fast-track is closed to Indian files, and the article that says otherwise is quoting a list it has not read. Article 11-4 of the Law on Medicines and Pharmaceutical Activities splits registration into a recognition regime and a national regime. The recognition regime is a homology check only – no repeat expertise, entry in the registry within seven working days – but it is available only for products already authorised by a regulator on the list fixed by Government Resolution No. 188 of 22 October 2009. That list was amended three times, adding Israel in 2013, Croatia in 2021 and Turkiye in 2022, and it contains the EMA, the United States, Japan, Canada, Australia, Korea, Switzerland, Norway and the EU and EEA member states. It does not contain India, CDSCO or WHO Prequalification. A liberal regime is not automatically an open one.
The national regime is the real route, and it is genuinely benign. Article 11-11 gives a fourteen-day administrative completeness check, a three-month decision period for a first registration, twenty calendar days for a Type IA variation and forty for a Type IB, and a two-month cure period for deficiencies which the Agency may raise only twice. Most strikingly, Article 11-11(10) provides that if the applicant is not notified of a refusal within the statutory period the product is considered registered and the authorisation document must be issued. Circulation is permitted for five years, and re-registration must be filed no later than two months before expiry or the product falls back to a primary application.
WHO-GMP is expressly enough – this is the single most important fact for an Indian site. Government Resolution No. 349 of 16 November 2010 lists the GMP standards Georgia recognises, and WHO-GMP heads that list alongside EC GMP, US FDA cGMP and PIC/S GMP. Its Article 1-prime obliges the registering body to accept a manufacturing-compliance document issued by a competent authority under any of those standards. Georgia's own national GMP standard is EC GMP, but that obligation runs to holders of Georgian manufacturing permits – domestic plants – not to importers. You do not need an EU-GMP certificate to file a WHO-GMP injectable in Georgia.
The fee is trivial and the price is capped by statute – model the ceiling, not the volume. Under the Law on Registration Fees a generic registration in the national regime costs GEL 500, a re-registration GEL 200, and a Type II documentation variation GEL 50, against GEL 2,500 for a new original product. At the other end, the Law on Medicines defines reference wholesale and retail prices as statutory maxima, obliges the Ministry to publish a reference price catalogue, and prohibits selling above it – with import, export and re-export transactions expressly carved out. In a market where the World Bank puts out-of-pocket spending at 58.76% of current health expenditure, a legislated ceiling structurally favours the cheapest compliant supplier.
Introduction: Why Georgia Demands a Premium Injectable Manufacturer in Georgia
Georgia is a small, wealthy-for-its-region market that punishes assumptions. The World Bank puts the population at 3,935,766 and gross national income per capita at US$8,990 for 2025, with current health expenditure at 6.86% of GDP and US$554.32 per person in 2023 – figures that sit well above most of the markets an Indian injectable exporter works in. But 58.76% of that health spending came out of patients' own pockets in 2023, which is the number that actually governs commercial behaviour. Price is not a secondary consideration in a majority out-of-pocket market; it is the first one. The therapeutic demand is real and injectable-heavy: GLOBOCAN 2024 records 16,063 new cancer cases and 7,780 cancer deaths a year in Georgia with 45,921 people alive within five years of a diagnosis, WHO estimates 1,700 tuberculosis cases in 2024, and the European Union Agency for Asylum's December 2025 medical country report – citing Georgia's National Center for Disease Control – records renal failure prevalence of 102.2 per 100,000 with haemodialysis available in 50 of the country's 64 municipalities as of July 2025 under a state dialysis and kidney transplant programme that covers the cost of treatment.
What makes Georgia genuinely distinctive is its regulatory architecture, and it is almost universally described incorrectly in supplier marketing. Georgia unilaterally recognises the decisions of a fixed list of foreign regulators and, for products they have approved, carries out no repeat scientific assessment at all – an unusually generous piece of regulatory policy for a country of four million people. That has produced a stream of content promising seven-working-day registration in Georgia. For a manufacturer whose product is registered in India and made to WHO-GMP, that promise does not apply, because India is not one of the recognised regulators. The useful article is the one that says so in the first paragraph and then explains, accurately, what the route that is open actually requires. That is what follows.
What Sets a World-Class Injectable Manufacturer in Georgia Apart
The national regime has an unusual shape and it rewards preparation in places an Indian regulatory affairs team will not expect. Article 11-11 of the Law on Medicines requires that the applicant be the manufacturer of the product or a trade licence holder – unlike the recognition route, which any interested person may use. It then splits the dossier in two: the administrative part must be filed in tangible form in the Georgian language, while the scientific and technical part may be filed in Georgian, Russian or English, in three identical paper copies, with an electronic copy alongside. The administrative part wants an original certificate of a pharmaceutical product in the form recommended by the World Health Organization or, where one is not available, a document certifying manufacture to the GMP standard or a manufacturing licence issued by the authority of the manufacturing country, plus an attested Georgian translation of the patient information leaflet and a standard pack. For a generic, the scientific part wants composition per dose unit, active substance monographs with the name and address of every API manufacturer, excipient monographs, finished-product specifications and methods, a manufacturing process flow chart, stability data and equivalence data determined according to WHO recommendations having regard to the dosage form and route of administration.
Two of those requirements are logistics problems rather than paperwork problems, and they are what separate a supplier who can actually execute in Georgia from one who cannot. The first is physical: two standard packs plus enough material for two tests with certificates of analysis, and a reference standard sufficient for two tests, also with a certificate. For a lyophilised or cold-chain injectable that is a genuine shipping, customs and stability exercise, not an envelope. The second is translation: an attested Georgian leaflet and a Georgian-language administrative file, produced to a standard that survives an Agency reading, at the same time as a Russian or English technical file. Neither is expensive relative to the GEL 500 statutory fee for a generic, but both take calendar time, and calendar time is the scarce resource when the Agency's own clock is only three months and it will accept deficiency responses on only two occasions before it decides.
Quality Systems Behind Every Injectable Supplied to Georgia
Georgia's acceptance of WHO-GMP is a legal position, not an informal courtesy, and it is worth stating precisely because so much competitor content implies that only a stringent authority certificate will do. Government Resolution No. 349 of 16 November 2010 sets out the list of international, regional and national GMP standards Georgia recognises, and WHO-GMP appears as the first item, followed by EC GMP, US FDA current GMP and PIC/S GMP. The resolution goes further and obliges the registering body to accept a manufacturing compliance document issued by a competent authority in accordance with any recognised standard. Georgia has separately adopted EC GMP as its national standard, but that adoption governs holders of Georgian manufacturing permits – the domestic plants – rather than foreign manufacturers filing an import registration.
There is one live uncertainty that any honest supplier should hand you rather than paper over. Georgia adopted a government resolution in March 2022 dealing with the stages and conditions under which the GMP compliance document must be submitted for products in both regimes, and its consolidated text was not publicly retrievable when this article was prepared. Secondary commentary attaches dates and consequences to it that we are not willing to repeat, because we could not read the instrument. The correct step before you commit budget is to request the current text and the Agency's present practice directly from the Regulation Agency for Medical and Pharmaceutical Activities, and to ask specifically whether a WHO-GMP certificate for the finished dosage form is still sufficient on its own. That question takes one email and removes the only material unknown in an otherwise well-documented pathway.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Georgia for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling on ISO Class 5 aseptic lines and exporting to more than 30 countries. For Georgia that starting point is decisive rather than incidental: because Resolution No. 349 places WHO-GMP at the head of the recognised standards and obliges the registering body to accept a compliance document issued under it, our existing certification is the certification the national regime asks for. We do not need to manufacture a second qualification, and you do not need to wait for one. Our quality systems are built around release testing by HPLC and GC, endotoxin control by LAL, moisture determination by Karl Fischer, and stability generated under ICH Q1A(R2) and Q1B, with a Site Master File and per-product documentation maintained in a form that authenticates cleanly for foreign filings.
We also build the file the way Georgia wants it rather than the way we already have it. Our dossiers are prepared in CTD and ACTD structure for the markets that require those, and for Georgia we reorganise the same underlying data into the statutory administrative and scientific-technical split, supply the API manufacturer names and addresses the generic checklist calls for by name, provide the process flow chart, and prepare the equivalence justification appropriate to the dosage form and route – which for most sterile solutions for injection is a reasoned argument rather than a clinical study. We produce the physical deliverables as a planned shipment: two standard packs, test quantities and a reference standard, each with its certificate of analysis, packed and documented so that customs and cold chain do not become the reason a three-month clock is missed. Artwork and leaflet content are supplied in a form ready for Georgian translation and attestation.
Finally, we price for the market that actually exists. Georgia legislates maximum wholesale and retail prices through a published reference price catalogue and prohibits sale above them, while 58.76% of health spending comes from households directly. That combination rewards a manufacturer whose cost base allows it to sit comfortably under a statutory ceiling and still supply consistently, which is precisely the position a Gujarat-based WHO-GMP injectable plant occupies. India already supplies this market: India's own reported exports of pharmaceutical products under HS Chapter 30 to Georgia were about US$24.8 million in 2024 and US$23.7 million in 2025, and India's Ministry of External Affairs lists medicines among its top export commodities to Georgia. There is no India-Georgia pharmaceutical or health memorandum of understanding in the bilateral inventory, so nothing about this trade rests on a government-to-government arrangement – it rests on suppliers who register properly and deliver. Write to director@farbefirma.org with the molecule, presentation and volume and we will map the filing route with you.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Can an Indian manufacturer use Georgia's seven-day recognition route?
No. The recognition regime is available only for products already authorised by a regulator on the list fixed by Government Resolution No. 188 of 22 October 2009, as amended in 2013, 2021 and 2022 to add Israel, Croatia and Turkiye. That list covers the EMA, the United States, Japan, Canada, Australia, New Zealand, Korea, Switzerland, Norway and the EU and EEA member states. India, CDSCO and WHO Prequalification are not on it. An Indian-registered, WHO-GMP product therefore files under the national regime. It is worth noting that the recognition route is also less generous than commonly claimed: the resulting authorisation tracks the foreign approval but is capped at five years by statute, so the widely repeated claim that it confers unlimited validity is simply wrong.
Is a CTD or eCTD dossier required to register an injectable in Georgia?
The statute does not prescribe the ICH Common Technical Document. It prescribes a Georgian-specific structure – an administrative part in the Georgian language in tangible form, and a scientific and technical part in Georgian, Russian or English in three identical paper copies with an electronic copy – and then lists the contents of each. Practically, a well-built CTD Module 3 contains almost everything the generic checklist asks for, so the work is reorganisation and translation rather than regeneration. Whether the Agency will accept a dossier physically organised in CTD modules is a question of current practice that we suggest confirming with the Agency, because the law neither requires nor forbids it.
Does Georgia accept a WHO-GMP certificate, or is EU-GMP needed?
WHO-GMP is expressly recognised. Government Resolution No. 349 of 16 November 2010 lists the GMP standards Georgia recognises, with WHO-GMP first, followed by EC GMP, US FDA current GMP and PIC/S GMP, and obliges the registering body to accept a manufacturing compliance document issued by a competent authority under any of them. Georgia's national GMP standard is EC GMP, but that requirement applies to holders of Georgian manufacturing permits rather than to importers. One caveat we state openly: a March 2022 government resolution governs the stages and conditions for submitting the GMP document, and we could not retrieve its consolidated text, so we recommend confirming current practice with the Regulation Agency for Medical and Pharmaceutical Activities before filing.
What does registration cost and how long does it take?
Under the Law on Registration Fees, a generic or repeatedly manufactured product in the national regime costs GEL 500 to register and GEL 200 to re-register, a new original product costs GEL 2,500, and a Type II variation in registration documentation costs GEL 50. On timing, the Agency has fourteen days for the administrative completeness check and three months to decide a primary registration, two months for re-registration, forty calendar days for a Type IB variation and twenty for a Type IA. Deficiencies may be raised on only two occasions with a cure period of up to two months, and if the applicant is not notified of a refusal within the statutory period the product is considered registered. Circulation is then permitted for five years.
Do I need an import licence, and can a foreign manufacturer sell into state tenders?
For ordinary sterile injectables no separate import permit is created by the Law on Medicines. Wholesale distribution, which by definition includes import, export and re-export, is subject to mandatory notification of the Agency rather than to a licence, and an import or export permit is required only for products under special control such as narcotics, psychotropics and precursors. On procurement, the consolidated Law on Public Procurement defined a participating person to include a legal person of a foreign country and required fair and non-discriminatory treatment, with foreign-language qualification documents accepted subject to a Georgian translation. Georgia adopted a new Public Procurement Law in February 2023 whose main body applies from 1 January 2025, and we have not verified how it treats foreign bidders, so confirm the current position with the State Procurement Agency before bidding.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments